Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib

Parsaclisib demonstrates improvement in symptoms and SV in MV patientsПодробнее

CITADEL-203: parsaclisib in R/R follicular lymphomaПодробнее

Long-Term Efficacy and Safety Results from a Phase 2 StudyПодробнее

Results of Phase II trial to assess the efficacy and safety of idelalisibПодробнее

Parsaclisib for MCL: next steps?Подробнее

CITADEL-204: safety and efficacy of parsaclisib in R/R MZLПодробнее

CITADEL-205: parsaclisib for R/R MCLПодробнее

Insights into Phase I/II study assessing fixed-duration glofitamab treatment for R/R LBCLПодробнее

Insights into a Phase II study evaluating ANX005 in wAIHAПодробнее

Phase 2 Clinical Trial: Evaluating the Efficacy and Safety of MAF Triple for Aging and LongevityПодробнее

The safety and efficacy of parsaclisib in autoimmune hemolytic anemiaПодробнее

Efficacy and safety results of a randomised controlled phase III studyПодробнее

Results of Phase II study of tislelizumab in R/R NK/T-cell neoplasmsПодробнее

Insights into a Phase I/II study assessing golidocitinib in PTCLПодробнее

Clinical efficacy and safety of CT-P10 in patients with DLBCLПодробнее

Phase III MF studies evaluating parsaclisib + ruxolitinib in treatment naive & suboptimal respondersПодробнее

Addition of Parsaclisib in Patients with Myelofibrosis | Abdulraheem Yacoub, MD | Open Mic MayПодробнее

ENERGY: Phase II/III study of nipocalimab in patients with wAIHAПодробнее

CITADEL-205: Parsaclisib in R/R MCLПодробнее